Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

CHMP Recommends Pfizer's Paxlovid For Use In Adults With COVID-19

The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending the conditional approval of Pfizer Inc's (NYSE:PFE) Paxlovid.

  • Paxlovid (nirmatrelvir and ritonavir tablets) is indicated for COVID-19 in adults who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19.
  • The CHMP based its positive opinion on the scientific evidence supporting PAXLOVID, including data from the Phase 2/3 EPIC-HR.
  • The data showed that Paxlovid reduced the risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo, with no deaths observed in the treatment group. 
  • Related: Pfizer's COVID-19 Oral Antiviral Shows In-Vitro Efficacy Against Omicron Variant.
  • Paxlovid is approved or authorized for emergency use in more than ten countries.
  • Pfizer has raised its production projections, with the potential ability to produce up to 120 million courses of treatment by the end of 2022.
  • PAXLOVID is administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice daily for five days. 
  • Price Action: PFE shares are up 2.18% at $54.17 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.